CD8A and neoplasm: Despite experimental differences of either employing sgRNA-mediated inactivation of Regnase-1 or Roquin-1 or introducing point mutations, which disrupt the interaction of both RBPs, all studies report increased proliferation and persistence of the tumor-antigen-specific CD8+ T cells or CAR T cells in the tumor as well as efficient inhibition of tumor growth (30, 57, 58, 62).